Answers are grounded in this paper and cite their sources.
Combined immunotherapy with nivolumab and ipilimumab has become the standard first-line therapy regimen for intermediate and poor-risk patients with renal cell carcinoma (RCC) specifically those with clear cell (ccRCC) and sarcomatous components.
No takes yet. Share an insight, caveat, or question.
Drobniak et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: